| 4.72 -0.31 (-6.16%) | 11-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.93 |
1-year : | 6.62 |
| Resists | First : | 5.08 |
Second : | 5.67 |
| Pivot price | 4.82 | |||
| Supports | First : | 4.11 |
Second : | 3.42 |
| MAs | MA(5) : | 5.03 |
MA(20) : | 4.82 |
| MA(100) : | 4.98 |
MA(250) : | 5.16  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.7 |
D(3) : | 59 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 11.89 | Low : | 3.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CING ] has closed above bottom band by 42.5%. Bollinger Bands are 55.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.98 - 5.01 | 5.01 - 5.03 |
| Low: | 4.58 - 4.62 | 4.62 - 4.65 |
| Close: | 4.66 - 4.72 | 4.72 - 4.77 |
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Tue, 03 Nov 2026
Cingulate Inc. (CING) Stock Price | Live Quotes & Charts | NASDAQ - www.timothysykes.com
Sat, 31 Oct 2026
Cingulate Inc. (CING) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Sat, 31 Oct 2026
Cingulate Inc. (CING) Seasonal returns chart - Yahoo Finance UK
Fri, 30 Oct 2026
Cingulate Inc. (CING) Seasonal returns chart - Yahoo Finance Australia
Tue, 25 Aug 2026
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) - The Globe and Mail
Fri, 26 Jun 2026
CING Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 28.2 (%) |
| Held by Institutions | 12.6 (%) |
| Shares Short | 1,030 (K) |
| Shares Short P.Month | 1,060 (K) |
| EPS | -3.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -67 % |
| Return on Equity (ttm) | -198.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.59 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | 0 |
| Price to Book value | 2.79 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|